Related Experiment Video
Updated: Jul 12, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic Effects of S89K Matrix Protein of Vesicular Stomatitis Virus in Cervical Cancer
Mehdi Ajorloo1, Ashkan Alamdary2, Samira Samaie3
1Biological Products and Blood Safety Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Background:
Oncolytic viruses are currently the subject of cancer treatment research. Unlike other viruses, they can target tumor cells while avoiding healthy ones. The vesicular stomatitis virus (VSV) has the ability to kill tumor cells through one of two different apoptotic pathways, depending on which cell line is being studied. Even when no other viral components are present, the VSV matrix protein can induce cell death in HeLa cells through apoptosis. The purpose of this research was to examine the similarities and differences in the induction of cell death by native and mutant VSV matrix proteins.
Materials And Methods:
To create the mutant VSV matrix protein, the amino acid Ser was substituted with Lys at residue 89 (S89K). After the matrix gene was cloned into the expression vector, both the normal and mutant versions were transfected into HeLa cells. The expression was verified by fluorescence microscopy, and flow cytometry was used to evaluate the apoptosis rate.
Results:
After 48 hours of transfection, the VSV matrix protein was found to promote cell death at the highest level. The results showed that once basic amino acids were substituted with alcoholic ones in the S89K mutant, the apoptotic activity of the VSV matrix protein was enhanced.
Conclusion:
This study discovered that increasing apoptosis induction by introducing a specific mutation at a specific location in the VSV matrix protein improved its apoptotic capabilities. The ability to engineer recombinant viruses with specific mutations is crucial for the development of cancer vaccines that target specific cell lines.
Insights
Researchers modified the vesicular stomatitis virus (VSV) matrix protein to enhance its tumor-killing ability. A specific mutation significantly boosted apoptosis induction, showing potential for targeted cancer vaccines.
Area of Science:
- Oncolytic virotherapy
- Molecular oncology
- Virology
Background:
- Oncolytic viruses selectively target and destroy tumor cells.
- Vesicular stomatitis virus (VSV) matrix protein induces apoptosis in tumor cells.
- VSV matrix protein's apoptotic pathway varies by cell line.
Purpose of the Study:
- Investigate cell death induction by native and mutant VSV matrix proteins.
- Compare apoptosis mechanisms of wild-type and engineered VSV matrix proteins.
Main Methods:
- Created a mutant VSV matrix protein (S89K) by substituting Serine with Lysine at residue 89.
- Transfected HeLa cells with native and mutant VSV matrix genes.
- Verified protein expression via fluorescence microscopy and assessed apoptosis rates using flow cytometry.
Main Results:
- VSV matrix protein maximally promoted cell death 48 hours post-transfection.
- The S89K mutation, substituting basic amino acids with alcoholic ones, enhanced the matrix protein's apoptotic activity.
- Engineered VSV matrix protein demonstrated increased tumor cell apoptosis.
Conclusions:
- Specific mutations in VSV matrix protein can enhance its apoptotic capabilities.
- Targeted engineering of oncolytic viruses is vital for developing effective cancer vaccines.
- This research advances the potential of VSV-based oncolytic virotherapy.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytomegalovirus Disease

